Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT) today. The company’s shares closed yesterday at $116.03.
Singh noted:
“Sarepta and its private company partner Myonexus are poised to present the first early stage MYO-101 data from its Limb-girdle muscular dystrophy type 2E (LGMD2E) program in 1Q19. Our analysis of the program and related AAVrh74-vector targets in LGMD2D, LGMD2B and DMD leads us to believe the risk/reward to this early stage data readout (Feb./Mar. we believe) is oriented to the upside. Strong expression levels of the SGCB transgene (70-90%) could be worth a 20% stock move; could be higher if the data gives greater overall visibility to the other LGMD programs. However, with AAV manufacturing still a near-term bottleneck and some risk around clinical development timelines, risks to LGMD programs are still non-trivial. Maintain Perform.”
According to TipRanks.com, Singh is a 2-star analyst with an average return of 0.3% and a 41.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Syndax Pharmaceuticals Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $196.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $50.68. Currently, Sarepta Therapeutics has an average volume of 1.01M.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 6,667 shares for a total of $936,714.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
